Outcome after curative resection for locally recurrent rectal cancer

2004 ◽  
Vol 11 (S2) ◽  
pp. S108-S108
Author(s):  
I. Bedrosian ◽  
G. Giacco ◽  
L. Pederson ◽  
M. Rodriguez-Bigas ◽  
B. Feig ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Curative Resection ◽  
Recurrent Rectal Cancer ◽  
Locally Recurrent Rectal Cancer ◽  
Locally Recurrent

Usefulness of carcinoembryonic antigen doubling time in prognosis prediction after curative resection of locally recurrent rectal cancer: A retrospective study

2021 ◽  
Author(s):  
JUNICHI SAKAMOTO ◽  
Heita Ozawa ◽  
Hiroki Nakanishi ◽  
Shin Fujita
Keyword(s):  
Rectal Cancer ◽  
Carcinoembryonic Antigen ◽  
Curative Resection ◽  
Doubling Time ◽  
Multivariate Analyses ◽  
Recurrent Rectal Cancer ◽  
Oncologic Outcomes ◽  
Prognosis Prediction ◽  
Locally Recurrent Rectal Cancer ◽  
Locally Recurrent

Introduction: Given that doubling time is an indicator of tumor growth, we assessed the usefulness of carcinoembryonic antigen doubling time (CEA-DT) in prognosis prediction after curative resection for locally recurrent rectal cancer. Methods: During January 1986 to December 2016, 33 patients with locally recurrent rectal cancer who underwent curative resection at our hospital were retrospectively reviewed. The primary endpoint was the 3-year recurrence-free survival (RFS) rate. The Kaplan-Meier method was used to compare RFS rates and evaluate univariate and multivariate analyses for factors associated with oncologic outcomes, including CEA-DT. CEA-DT was classified into two groups: the short and long CEA-DT groups. Results: The 3-year overall survival and RFS rates were 62.6% and 42.4%, respectively. In multivariate analyses, CEA-DT was an independent risk factor for poor RFS. The 3-year RFS rate was significantly better in the long CEA-DT group than in the short CEA-DT group (58.8% vs. 25.0%, p = 0.0063). Conclusion: CEA-DT is a useful prognostic factor that can be assessed before surgery for locally recurrent rectal cancer. Long CEA-DT may indicate a favorable prognosis. Contrarily, short CEA-DT is associated with poor prognosis; therefore, further treatment intervention is necessary for patients with short CEA-DT.

VOLTAGE-B study: Nivolumab monotherapy and subsequent curative surgery following preoperative chemoradiotherapy in patients with locally recurrent rectal cancer (LRRC) without previous radiotherapy.

2020 ◽  
Vol 38 (4_suppl) ◽  
pp. 100-100
Author(s):  
Takeshi Kato ◽  
Hideaki Bando ◽  
Yuichiro Tsukada ◽  
Koji Inamori ◽  
Mamoru Uemura ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Curative Resection ◽  
Tumor Regression ◽  
Pathologic Complete Response ◽  
Recurrent Rectal Cancer ◽  
Curative Surgery ◽  
Locally Recurrent Rectal Cancer ◽  
Primary Rectal Cancer ◽  
Locally Recurrent ◽  
Grade 3

100 Background: Chemoradiotherapy (CRT) followed by curative resection in patients (pts) with local recurrence after radical surgery for primary rectal cancer is the preferred strategy if radiotherapy (RT) was not previously performed. In VOLTAGE-A study, nivolumab plus surgery following CRT showed a promising pathologic complete response (pCR) rate of 30% in pts with microsatellite-stable (MSS) advanced primary rectal cancer. The treatment sequence was prospectively investigated in pts with Locally Recurrent Rectal Cancer (LRRC) in VOLTAGE-B. Methods: Pts with pelvic LRRC without previous RT were included. Five cycles of nivolumab (240 mg q2 weeks) plus curative surgery following CRT (50.4 Gy with capecitabine 1,650 mg/m2) were performed. The pCR rate using AJCC tumor regression grading and curative resection rate were key endpoints. Planned sample size in VOLTAGE-B was set 10 pts in an exploratory manner. Results: From May to Oct 2018, 10 pts were included. Median age was 65 and 8 were male. Curative resection was performed in nine pts with MSS. One had a newly diagnosed supraclavicular lymph node metastasis before surgery. As one pt with AJCC grade 0, seven with grade 2, and one with grade 3, were observed, pCR rate was 10%. As of cut-off date of Apr 2019, three pts showing recurrence out of the nine pts were observed. Nivolumab-related adverse events (AEs) were only one pt with grade 1 hyperthyroidism and one with grade 1 erythema. Grade 3/4 surgery-related AEs were observed in six pts, including two pts with ileus and two with pelvic infections. No treatment-related deaths were observed. Conclusions: The pCR rate of 10% with acceptable toxicity was shown in MSS LRRC pts treated with nivolumab plus curative surgery following CRT. Translational research exploring better predictors of efficacies of study treatment are ongoing. Clinical trial information: NCT02948348.

Locally recurrent rectal cancer after curative resection

2004 ◽  
Vol 8 (S1) ◽  
pp. s132-s134 ◽  
Author(s):  
E. Christoforidis ◽  
I. Kanellos ◽  
T. Tsachalis ◽  
K. Blouhos ◽  
I. Lamprou ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Curative Resection ◽  
Recurrent Rectal Cancer ◽  
Locally Recurrent Rectal Cancer ◽  
Locally Recurrent

Outcome After Curative Resection for Locally Recurrent Rectal Cancer

2006 ◽  
Vol 49 (2) ◽  
pp. 175-182 ◽  
Author(s):  
Isabelle Bedrosian ◽  
Geoffrey Giacco ◽  
Lee Pederson ◽  
Miguel A. Rodriguez-Bigas ◽  
Barry Feig ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Curative Resection ◽  
Recurrent Rectal Cancer ◽  
Locally Recurrent Rectal Cancer ◽  
Locally Recurrent

scholarly journals Intraoperative Electron Radiation Therapy (IOERT) in the management of locally recurrent rectal cancer

BMC Cancer ◽  
2012 ◽  
Vol 12 (1) ◽  
Author(s):  
Falk Roeder ◽  
Joerg-Michael Goetz ◽  
Gregor Habl ◽  
Marc Bischof ◽  
Robert Krempien ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Radiation Therapy ◽  
Recurrent Rectal Cancer ◽  
Electron Radiation ◽  
Locally Recurrent Rectal Cancer ◽  
Locally Recurrent
Sign in / Sign up

Export Citation Format

Share Document